EUCTR2010-019584-10-FR进行中（未招募）1 期
A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys® and Copegus® versus Pegasys® and Copegus® alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection
F.Hoffmann-La Roche0 个研究点目标入组 405 人开始时间: 2010年9月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 405
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Adults patients, >/=18 years of age
- •- Chronic Hepatitis C, Genotype 1 and 4
- •- HCV RNA >/=50,000 IU/mL
- •- treatment-naive
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients with cirrhosis or incomplete/transition to cirrhosis
- •- Patients with other forms of liver disease, HIV infection, hepatocellular carcinoma or severe cardiac disease
研究者
相似试验
进行中（未招募）
不适用
A research study of a new medicine, danoprevir (also known as RO5190591) with ritonavir (also known as NORVIR®) in combination with Pegasys® (also known as PEG-IFN alfa-2a) and Copegus® (also known as ribavirin) for the treatment of a disease called chronic hepatitis C which causes damage to the liver.EUCTR2010-019584-10-GBF.Hoffmann-La Roche405
进行中（未招募）
不适用
A research study of a new medicine, danoprevir (also known as RO5190591) with ritonavir (also known as NORVIR®) in combination with Pegasys® (also known as PEG-IFN alfa-2a) and Copegus® (also known as ribavirin) for the treatment of a disease called chronic hepatitis C which causes damage to the liver.Chronic Hepatitis CMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-019584-10-ATF.Hoffmann-La Roche405
进行中（未招募）
不适用
A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys and Copegus versus Pegasys and Copegus alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection - DAUPHINEChronic Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912EUCTR2010-019584-10-ITHoffmann-La Roche405
进行中（未招募）
不适用
A research study of a new medicine, danoprevir (also known as RO5190591) with ritonavir (also known as NORVIR®) in combination with Pegasys® (also known as PEG-IFN alfa-2a) and Copegus® (also known as ribavirin) for the treatment of a disease called chronic hepatitis C which causes damage to the liver.Chronic Hepatitis CMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-019584-10-DEF.Hoffmann-La Roche405
进行中（未招募）
不适用
A study on the safety and effectiveness of BG00012 in children from 10 to less than 18 years old with a type of Multiple Sclerosis that is called Relapsing-Remitting Multiple Sclerosis.Relapsing-Remitting Multiple SclerosisMedDRA version: 16.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 16.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-002318-11-ITBiogen Idec Research Limited142